FAM86B3P

Across TCGA pan-cancer cohorts, FAM86B3P Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM86B3P data layer compared with 18 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher FAM86B3P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM86B3P expression acts as an unfavorable survival marker.

SARC and BLCA are the cancer types where FAM86B3P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.096	0.632	.003	12	view →
BLCA	DFS	Median	All	0.179	0.625	.029	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM86B3P–SARC (DFS)

Open the SARC breakdown →